ArticlePediatric research2026
Hyperuricemia in preterm infants: clinical features and early rasburicase therapy.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHyperuricemia is implicated in neonatal acute kidney injury. Although rasburicase effectively lowers uric acid (UA) in malignancy-associated hyperuricemia, evidence in preterm infants is scarce.
methodsWe retrospectively studied 74 preterm neonates ( ≤ 32 weeks or <1500 g). Infants with hyperuricemia (serum UA levels ≥8 mg/dL; n = 20) received single-dose intravenous rasburicase (0.2 mg/kg). Serial clinical data were collected.
resultsMedian serum UA levels peaked on day 1 (5.0 mg/dL), declining by day 28 (1.6 mg/dL). Hyperuricemia occurred in 20 infants (27.0%). Rasburicase was administered at a median postnatal age of 3 days with a median UA level of 9.6 mg/dL, a median postmenstrual age of 25 weeks and body weight of 667 g at the time of treatment. Rasburicase reduced UA by >90% within 24 h, increased urine output, and normalized electrolytes (all p < 0.05). Exposure to rasburicase was associated with a significant reduction in serum UA, independent of postnatal age, with a significant time-by-treatment interaction. Blood urea nitrogen and creatinine levels improved by day 7. No adverse effects were observed.
conclusionEarly rasburicase administration was associated with a marked reduction in serum UA levels and improvement in renal parameters without major adverse effects, suggesting a potential therapeutic role in preterm neonates. IMPACT: Hyperuricemia contributes to neonatal acute kidney injury (AKI) and is closely linked to prematurity and illness severity. Although rasburicase is established for malignancy-associated hyperuricemia, evidence in preterm infants remains limited. This is the first study to evaluate the efficacy and safety of early rasburicase in extremely preterm infants with hyperuricemia. Early rasburicase administration resulted in a rapid uric acid reduction of >90% and an association with favorable changes in renal parameters without observed adverse effects. Our findings provide novel evidence supporting rasburicase as a potential therapeutic option in neonatal intensive care to reduce hyperuricemia-related AKI risk.
Identifiers
42343104What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.